Drug Trial Radar · NCT00734864
Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
Last checked: Nov 19, 2026Latest source record: Nov 21, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2009
Primary completion
Jun 2010
Study completion Jun 2012
Sponsor
- Lead sponsor
- Annick DesjardinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bristol-Myers Squibb
- First posted
- Aug 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of dasatinib when combined with protracted, daily temozolomide (TMZ). Secondary objectives are: To further evaluate the safety and tolerability of dasatinib plus protracted, daily TMZ; 2. To evaluate the pharmacokinetics of dasatinib when administered with protracted, daily TMZ among recurrent malignant glioma patients who are on and not on CYP-3A enzyme inducing anti-epileptic drugs (EIAEDs); 3. To evaluate for anti-tumor activity with this regimen in this patient population.
Conditions
- Glioblastoma Multiforme
- Gliosarcoma
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Glioma
Interventions
enzyme-inducing anti-epileptic drugsDrug
Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
enzyme-inducing anti-epileptic drugsDrug
Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Toxicity assessed using CTCAE v.3.0Time frame: weekly
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.